No shared genetic risk variant or gene was identified in our patients of Northern-European origin, and none had the East-Asian variant in the ring finger protein RNF213. Identification of a de novo variant in the AGXT2 gene supports the hypothesis of NO pathway dysregulation as a key contributor and plausible risk factor in MMD pathophysiology. This evidence concerns the gene RNF213 and multiminicore myopathy.